Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risk-adapted treatment of newly diagnosed acute myeloid leukemia with or without G-CSF
NL-OMON27294Phase 3Active, not recruiting
- Sponsor
- HOVON
- Start
- Mar 1995
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of filgrastim, idarubicin, cytarabine, amsacrine, mitoxantrone and 3 more in acute myeloid leukemia (AML) (6 arms), sponsored by HOVON. Primary endpoint: Complete remission rate. Started Mar 1995; status: active, not recruiting.
02
Drugs
filgrastimidarubicincytarabineamsacrinemitoxantrone
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON27294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27294.